Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 3/20 | 0.48 |
| ▸ | MPO | P05164 | 12/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | TPO | P07202 | 11/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21530676 | 1.00 | ADORA2A (0.48) | ADORA2AMPOOPRM1PDE4APDE4B | |
| SCHEMBL21530641 | 0.80 | MPO (0.63) | ADORA2AMPOOPRM1TPOCYP3A4 | |
| SCHEMBL562265 | 0.76 | PDE4A (0.64) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL561896 | 0.76 | PDE4A (0.64) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL561895 | 0.76 | PDE4A (0.64) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL562982 | 0.72 | PDE4A (0.70) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL562981 | 0.72 | PDE4A (0.70) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL21530655 | 0.71 | ADORA2A (0.53) | ADORA2AADORA2B | |
| SCHEMBL7099892 | 0.70 | ADORA2A (0.47) | ADORA2ACYP3A4ADORA2B | |
| SCHEMBL12237731 | 0.69 | PNP (0.39) | ADORA2APDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115279766-B | Combination therapy comprising A2A/A2B and a PD-1/PD-L1 inhibitor | 因赛特公司 | 2025-05-02 | — | — | CN | disclosed |
| US-20250059293-A1 | CD73 INHIBITOR AND A2A/A2B ADENOSINE RECEPTOR INHIBITOR COMBINATION THERAPY | INCYTE CORPORATION | 2025-02-20 | — | — | US | disclosed |
| US-20250041310-A1 | Combination Therapy Comprising A2A/A2B and PD-1/PD-L1 Inhibitors | INCYTE CORPORATION | 2025-02-06 | — | — | US | disclosed |
| US-12060433-B2 | CD73 inhibitor and A2A/A2B adenosine receptor inhibitor combination therapy | INCYTE CORPORATION (US) | 2024-08-13 | — | — | US | disclosed |
| CN-117500503-A | Combination therapy comprising an A2A/A2B inhibitor, a PD-1/PD-L1 inhibitor and an anti-CD 73 antibody | 因赛特公司 | 2024-02-02 | — | — | CN | disclosed |
| EP-4271384-A1 | COMBINATION THERAPY COMPRISING A2A/A2B INHIBITORS, PD-1/PD-L1 INHIBITORS, AND ANTI-CD73 ANTIBODIES | Incyte Corporation (US) | 2023-11-08 | — | — | EP | disclosed |
| CN-115551595-A | Combination therapy of a CD73 inhibitor and an A2A/A2B adenosine receptor inhibitor | 因赛特公司 | 2022-12-30 | — | — | CN | disclosed |
| EP-4084870-A1 | CD73 INHIBITOR AND A2A/A2B ADENOSINE RECEPTOR INHIBITOR COMBINATION THERAPY | Incyte Corporation (US) | 2022-11-09 | — | — | EP | disclosed |
| EP-4085060-A1 | COMBINATION THERAPY COMPRISING A2A/A2B AND PD-1/PD-L1 INHIBITORS | Incyte Corporation (US) | 2022-11-09 | — | — | EP | disclosed |
| CN-115279766-A | Combination therapy comprising A2A/A2B and PD-1/PD-L1 inhibitors | 因赛特公司 | 2022-11-01 | — | — | CN | disclosed |
| US-20220233529-A1 | COMBINATION THERAPY COMPRISING A2A/A2B INHIBITORS, PD-1/PD-L1 INHIBITORS, AND ANTI-CD73 ANTIBODIES | INCYTE CORPORATION | 2022-07-28 | — | — | US | disclosed |
| WO-2022147092-A1 | COMBINATION THERAPY COMPRISING A2A/A2B INHIBITORS, PD-1/PD-L1 INHIBITORS, AND ANTI-CD73 ANTIBODIES | INCYTE CORPORATION (US) | 2022-07-07 | — | — | WO | disclosed |
| US-11220510-B2 | Pyrrole tricyclic compounds as A2A / A2B inhibitors | INCYTE CORPORATION (US) | 2022-01-11 | — | — | US | disclosed |
| US-20210230294-A1 | CD73 INHIBITOR AND A2A/A2B ADENOSINE RECEPTOR INHIBITOR COMBINATION THERAPY | INCYTE CORPORATION | 2021-07-29 | — | — | US | disclosed |
| WO-2021138498-A1 | CD73 INHIBITOR AND A2A/A2B ADENOSINE RECEPTOR INHIBITOR COMBINATION THERAPY | INCYTE CORPORATION (US) | 2021-07-08 | — | — | WO | disclosed |
| WO-2021138512-A1 | COMBINATION THERAPY COMPRISING A2A/A2B AND PD-1/PD-L1 INHIBITORS | INCYTE CORPORATION (US) | 2021-07-08 | — | — | WO | disclosed |
| US-20190337957-A1 | PYRROLE TRICYCLIC COMPOUNDS AS A2A / A2B INHIBITORS | INCYTE CORPORATION | 2019-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12060433-B2 | CD73 inhibitor and A2A/A2B adenosine receptor inhibitor combination therapy | ADORA2A, ADORA2B, NT5E | ADORA2A 1/4885MPO 1637/4885OPRM1 2519/4885 |
| US-20220233529-A1 | COMBINATION THERAPY COMPRISING A2A/A2B INHIBITORS, PD-1/PD-L1 INHIBITORS, AND ANTI-CD73 ANTIBODIES | ADORA2A, ADORA2B, ENTPD1 | ADORA2A 1/4885MPO 1921/4885OPRM1 2145/4885 |
| US-20250059293-A1 | CD73 INHIBITOR AND A2A/A2B ADENOSINE RECEPTOR INHIBITOR COMBINATION THERAPY | ADORA2A, ADORA2B, NT5E | ADORA2A 1/4885MPO 1637/4885OPRM1 2519/4885 |
| US-20190337957-A1 | PYRROLE TRICYCLIC COMPOUNDS AS A2A / A2B INHIBITORS | ADORA2A, ADORA2B, ADORA1 | ADORA2A 1/4885MPO 3253/4885OPRM1 725/4885 |
| US-20250041310-A1 | Combination Therapy Comprising A2A/A2B and PD-1/PD-L1 Inhibitors | ADORA2A, ADORA2B, ADORA1 | ADORA2A 1/4885MPO 4266/4885OPRM1 300/4885 |
| US-20210230294-A1 | CD73 INHIBITOR AND A2A/A2B ADENOSINE RECEPTOR INHIBITOR COMBINATION THERAPY | ADORA2A, ADORA2B, NT5E | ADORA2A 1/4885MPO 1637/4885OPRM1 2519/4885 |
| US-11220510-B2 | Pyrrole tricyclic compounds as A2A / A2B inhibitors | ADORA2A, ADORA2B, ADORA1 | ADORA2A 1/4885MPO 3253/4885OPRM1 725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.